Expert teams from Hong Kong Institute of Biotechnology, Fosun Kite and Peking University Shenzhen Ho
On January 18th, Dr.Gina, Director, Hong Kong Institute of Biotechnology (HKIB) Jiang,Dr. C.k. Wong, Deputy General manager of Hong Kong Biotechnology Research Institute Limited,Shen Hao, chief scientific officer of Fosun Kite Biotechnology Co., LTD,FChen Junhui, director of the Interventional and Cell Therapy Center of Peking University Shenzhen Hospital, and other expert teams visited Shenzhen Cell Valley.Shi Yuanyuan, Chairman and general Manager of Shenzhen Cell Valley, Wang Jianxun, Chief scientist, Sun Rui, Minister of Marketing, Yang Jianglong, Vice Minister; Wei Zheng, assistant chairman of the board, and Luan Zhishi, director of the Comprehensive Office, warmly received and had an in-depth discussion on the collaborative development of the cell and gene therapy industry.
Accompanied and explained by Chairman Shi Yuanyuan, the visiting experts visited the exhibition hall, production workshop and R&D laboratory of Shenzhen Cell Valley to further understand the company's development history, core team, advantages of retroviral vector used to prepare cell therapy products, four service platforms - virus products, cell products, auxiliary declaration, talent training, GMP level manufacture. Clinical application progress, major technological breakthroughs and enterprise comprehensive strength.
During the symposium, Chairman Shi Yuanyuan expressed a warm welcome to the guests and proposed that Shenzhen Cell Valley will join hands with HKIB, Fosun Kite, and Peking University Shenzhen Hospital to integrate leading enterprises, medical institutions, scientific research institutes and industries The advantageous resources of all parties in the service infrastructure CRO/CDMO platform, especially the special location advantages and supporting policies of Shenzhen and Hong Kong, create a Shenzhen-Hong Kong cooperation demonstration project where the two places jointly build innovative models and mechanisms for cell therapy.Dr. Gina Jiang, President of HKIB, introduced that HKIB is currently building Hong Kong's first GMP cell preparation laboratory entrusted by the Hong Kong Hospital Authority. It is expected that cell therapy products produced locally in Hong Kong will enter clinical practice in the first half of this year.Dr. Shen Hao, CSO of Fosun Kite, mentioned that axicabtagene ciloleucel, the first cell therapy drug to be launched in mainland China, has just been approved by the Hong Kong government and has become the second CAR-T drug that can be used in Hong Kong. Director Chen Junhui of Peking University Shenzhen Hospital said that the hospital has rich experience in IIT and IND clinical research on hematological tumors and solid tumors.Dr. Shi Yuanyuan introduced the recent major breakthroughs in the production and preparation of CAR-NK and CAR-γδT cells in Shenzhen Cell Valley, and said that with the support of policies and market demand, cell therapy is a key field of future medicine, and Shenzhen Cell Valley is deepening its production Academic and research cooperation, committed to building an open platform, cooperating with outstanding domestic and foreign teams and enterprises to promote the development of the cell and gene therapy industry chain.
All parties participating in the meeting conducted detailed and in-depth exchanges on the recent research progress and results of cell therapy products, core technologies and advantages, basic and clinical research, and enterprise construction and development, laying a solid foundation for exploring cooperation models and close cooperation in the later period. All parties agreed to rapidly advance cooperation, strive to open up the barriers to the industrialization and internationalization of cell therapy in the Mainland and Hong Kong, and explore a new development path for China's CGT industry.
All parties participating in the meeting conducted detailed and in-depth exchanges on the recent research progress and results of cell therapy products, core technologies and advantages, basic and clinical research, and enterprise construction and development, laying a solid foundation for exploring cooperation models and close cooperation in the later period. All parties agreed to rapidly advance cooperation, strive to open up the barriers to the industrialization and internationalization of cell therapy in the Mainland and Hong Kong, and explore a new development path for China's CGT industry.
